XML 39 R22.htm IDEA: XBRL DOCUMENT v3.19.1
CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (Tables)
12 Months Ended
Jan. 31, 2019
Schedule of outstanding warrants

A summary of warrants outstanding as of January 31, 2019 is as follows: 

 

 

 

 

 

 

 

 

 

Total

 

Price per Share

 

Expiration Date

Warrants related to January 2014 agreement

 

289,505

 

$ 1.85

 

May 2019

Warrants related to May 2014 agreement

 

316,395

 

$2.035

 

May 2019

Warrants related to April to November 2014 financing

 

1,661,055

 

$ 3.70

 

April 2019 - November 2019

Warrants related to June 2015 financing

 

109,091

 

$ 2.75

 

June 2020

Warrants related to April 2016 financing

 

1,952,000

 

$ 1.20

 

April 2021

Warrants related to September 2016 financing (1)

 

1,286,501

 

$ 0.75

 

September 2021 to March 2022

Warrants related to November 2016 financing

 

30,406,061

 

$ 0.35

 

November 2022 to November 2024

Warrants related to November 2016 financing

 

895,450

 

$ 0.44

 

November 2022

Warrants related to November 2016 financing

 

198,214

 

$ 0.33

 

November 2022

Warrants related to April 2017 financing

 

801,282

 

$ 0.90

 

October 2022

Warrants related to October 2017 financing (2)

 

3,846,152

 

$ 0.30

 

October 2022

Warrants related to November 2017 financing

 

56,935,191

 

$ 0.20

 

November 2022

Warrants related to November 2017 financing (3)

 

33,422,061

 

$ 0.25

 

May 2019

Warrants related to November 2018 financing (3)

 

26,666,666

 

$0.164

 

May/June 2021


(1)

In connection with the sale of common stock in September 2016, warrants to purchase 1,286,501 shares of common stock were issued at an exercise price of $0.75 per share. These warrants included a cash settlement option requiring the Company to record a liability for the fair value of the warrants at the time of issuance and at each reporting period with any change in the fair value reported as other income or expense. At the time of issuance, approximately $566,000 was recorded as a warrant liability. To value the warrant liability, the Company used the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.1%, contractual term of 5 years, expected volatility of 95.8% and a dividend rate of 0%. As of January 31, 2019, the fair value of the warrant liability was approximately $11,000 and was included as a long-term liability.

(2)

On October 23, 2017, the Company entered into agreements with certain of these warrant holders to permit their immediate exercise of 2,564,103 shares of common stock underlying the warrants at an exercise price per share of $0.24. The Company recorded a charge for the incremental fair value of approximately $151,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.03%, contractual term of 5 years, expected volatility of 83.9% and a dividend rate of 0%. In addition, these warrant holders were issued new warrants to purchase up to an aggregate of 3,846,152 shares of common stock at an exercise price per share of $0.30.

(3)

On November 20, 2018, the Company entered into agreements with holders of certain of its warrants to purchase common stock with an exercise price per share of $0.25 originally issued on November 24, 2017 (Existing Warrants), whereby the holders and the Company agreed that the holders would cash exercise  26,666,666 shares of common stock underlying such Existing Warrants at a reduced price of $0.14, and the Company would issue new warrants to such holders to purchase up to an aggregate of 26,666,666 shares of common stock (New Warrants). The New Warrants are exercisable after the six-month anniversary of their issuance and terminate on the 30-month anniversary following their issuance. The New Warrants have an exercise price per share of $0.164. The Company recorded a charge for the incremental fair value of approximately $874,000 in the other expense line item in the consolidated statements of operations and comprehensive loss. The fair value of the warrants exercised was computed as of the date of exercise using the following assumptions: risk-free interest rate of 2.51%, contractual term of 6 months, expected volatility of 78.4% and a dividend rate of 0%.

Schedule of significant ranges of outstanding and exercisable options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Outstanding

 

Options Vested and Exercisable

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

Weighted

 

 

 

Weighted

 

 

 

 

 

Remaining

 

Average

 

Number

 

Average

 

 

 

Number

 

Contractual

 

Exercise

 

Vested and

 

Exercise

 

Range of Exercise Prices

    

Outstanding

    

Life (in Years)

    

Prices

    

Exercisable

    

Prices

 

$0.10 - $0.16

 

5,503,893

 

8.09

 

$

0.11

 

2,619,037

 

$

0.10

 

$0.17 - $0.35

 

11,347,484

 

9.02

 

$

0.22

 

1,728,162

 

$

0.23

 

$0.36 - $0.65

 

2,567,126

 

6.12

 

$

0.53

 

1,974,108

 

$

0.53

 

$0.66 - $1.14

 

3,266,554

 

6.43

 

$

0.78

 

2,265,302

 

$

0.79

 

$1.15 - $3.00

 

1,037,812

 

3.25

 

$

1.79

 

1,003,748

 

$

1.80

 

 

 

23,722,869

 

7.88

 

$

0.37

 

9,590,357

 

$

0.55

 

 

2014 Equity Incentive Plan  
Stock option plan activity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

Remaining

 

Aggregate

 

 

 

Available for

 

 

 

Exercise

 

Contractual

 

Intrinsic

 

 

    

Grant

    

Shares

    

Prices

    

Life

    

Value

 

 

 

 

 

 

 

 

 

 

 

 

(in thousands)

 

Balance as of February 1, 2017

 

252,379

 

6,465,829

 

$

0.77

 

8.77

 

$

238

 

Shares authorized for issuance

 

20,000,000

 

 —

 

 

 

 

 

 

 

 

 

Granted

 

(18,553,000)

 

18,553,000

 

$

0.29

 

 

 

 

 

 

Exercised

 

 —

 

(40,000)

 

$

0.25

 

 

 

 

 

 

Canceled and returned to the 2016 Plan

 

185,499

 

(185,499)

 

$

0.65

 

 

 

 

 

 

Canceled subsequent to termination of the 2014 Plan

 

 —

 

(68,667)

 

$

1.48

 

 

 

 

 

 

Balance as of January 31, 2018

 

1,884,878

 

24,724,663

 

$

0.41

 

9.17

 

$

304

 

Shares authorized for issuance

 

50,000,000

 

 —

 

 

 

 

 

 

 

 

 

Granted

 

(10,444,000)

 

10,444,000

 

$

0.21

 

 

 

 

 

 

Exercised

 

 —

 

(278,196)

 

$

0.10

 

 

 

 

 

 

Canceled and returned to the 2016 Plan

 

11,262,538

 

(11,262,538)

 

$

0.30

 

 

 

 

 

 

Canceled subsequent to termination of the 2014 Plan

 

 —

 

(680,060)

 

$

1.01

 

 

 

 

 

 

Balance as of January 31, 2019

 

52,703,416

 

22,947,869

 

$

0.36

 

7.92

 

$

23

 

Vested and exercisable

 

 

 

9,257,545

 

$

0.53

 

5.93

 

$

13

 

Vested and expected to vest

 

 

 

21,836,056

 

$

0.37

 

7.85

 

$

22

 

 

Outside of the 2016 Equity Incentive Plan  
Stock option plan activity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

Average

 

Remaining

 

 

 

 

 

 

 

 

Exercise

 

Contractual

 

Aggregate

 

 

    

Shares

    

Prices

    

Life

    

Intrinsic Value

 

 

 

 

 

 

 

 

 

 

(in thousands)

 

Balance as of February 1, 2017 and 2018

 

660,000

 

$

1.44

 

7.72

 

$

 —

 

Granted

 

400,000

 

$

0.19

 

 

 

 

 

 

Canceled

 

(285,000)

 

$

1.65

 

 

 

 

 

 

Balance as of January 31, 2019

 

775,000

 

$

0.71

 

6.6

 

$

 —

 

Vested and exercisable

 

332,812

 

$

1.30

 

3.70

 

$

 —

 

Vested and expected to vest

 

747,437

 

$

0.73

 

6.52

 

$

 —